The Lancet Neurology in conversation with
The Lancet Neurology in conversation with
The Lancet Group
John Collinge on a treatment for CJD
14 minutes Posted Mar 16, 2022 at 11:00 pm.
0:00
14:45
Download MP3
Show notes

John Collinge (MRC Prion Unit, University College London, London, UK) discusses a first-in-human treatment programme to give PRN100, an anti-prion-protein monoclonal antibody, to patients with Creutzfeldt–Jakob disease; the report is published in the April issue of The Lancet Neurology.